Evidence mapPaperPMID 41405749Full record

ReviewDiscover nano2025

Neutrophil membrane-coated nanoparticles for targeted therapy.

Junjie Ma, Haixin Pei, Fuhang Wang, Deliang Shen

Abstract readReview
In one paragraph

Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Junjie MaDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Haixin PeiDivision of Endocrinology, Department of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Fuhang WangDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Deliang ShenDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China. dlshen@zzu.edu.cn.

Funding

the National Natural Science Foundation of China 82170271the Natural Science Foundation of Henan 241111311600
6 · The paper itself

Abstract

Traditional drug delivery systems often face problems such as low drug accumulation at the target site, rapid clearance in the body, and potential damage to healthy tissues. Under such circumstances, nanoparticle drug delivery systems have been developed. Although they have certain advantages, they still struggle to achieve efficient and specific targeting and may exhibit cytotoxicity. In contrast, neutrophil membrane-coated nanoparticles (NM-NPs) inherit the natural cell surface proteins and ligands of neutrophils, possessing numerous advantages such as low immunogenicity, immune evasion, and the ability to achieve precise targeting, thus showing great potential. This review is the first article to comprehensively summarize the application of neutrophil membrane-coated nanoparticles in targeted therapy. It mainly focuses on the pathophysiological role of neutrophils, the advantages of neutrophil membrane coating, the selection and preparation of nanoparticle cores, the targeting mechanism of neutrophil membrane-coated nanoparticles, the types of nano-drugs for targeted delivery, their application in disease treatment, and discussions on related safety and toxicology.

Indexed as

Drug delivery systemMembraneNanoparticlesNeutrophilTargeted therapy

Identifiers

PMID41405749
PMCPMC12712283

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.